X°Port Heart Preservation System
Traferox Technologies, Inc. · Decision date Sep 16, 2026
What did the FDA decide?
FDA recorded a substantially equivalent (SESE) decision for the X°Port Heart Preservation System, submitted by Traferox Technologies, Inc. of Mississauga, Canada, under 510(k) number K261913. The decision date is 16 September 2026; the application was received 8 June 2026. The device falls under classification name "System And Accessories, Isolated Heart, Transport And Preservation," regulation number 876.5880, product code MSB. The review panel is Cardiovascular, while the recorded regulation medical specialty is Gastroenterology/Urology. SESE means the device was cleared through the 510(k) pathway, not approved via PMA.
The record describes a traditional 510(k) that was not reviewed by a third party, is not a combination product, and has no authorized predetermined change control plan. The public page does not state which components or accessories are included, what changes, if any, were made relative to a predicate device, or what the basis for the equivalence finding was. No summary statement or clinical data appear in the available text. The page was last updated 28 September 2026.
Readers should treat this as a clearance record only. The available material does not support conclusions about clinical performance, patient selection, or labeling, and the specialty and panel fields differ, so the applicable review context should be confirmed against the underlying FDA documents.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Gastroenterology, Urology
- Decision date
- Sep 16, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K261913
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- Traferox Technologies, Inc.
- Product code
- MSB
- Decision code
- SESE
- Decision date
- Sep 16, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: System And Accessories, Isolated Heart, Transport And Preservation.
- Applicant
- Traferox Technologies, Inc.
- Product code
- MSB
- FDA device class
- 2
FDA decision timeline
K261913 received
Application receipt date recorded by FDA.
K261913 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
No additional submissions with a verified PMA or product-code relationship are linked here.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Traferox Technologies, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Mississauga
Sources and methodology
- Original FDA record: K261913
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records